Cargando…

Characterization of Aberrations in DNA Damage Repair Pathways in Gastrointestinal Stromal Tumors: The Clinicopathologic Relevance of γH2AX and 53BP1 in Correlation with Heterozygous Deletions of CHEK2, BRCA2, and RB1

SIMPLE SUMMARY: Aberrations of DNA damage repair (DDR) pathways enable the transformation of pre-neoplastic lesions, but their roles are barely understood in gastrointestinal stromal tumors (GISTs). The targeted next-generation sequencing of GISTs has demonstrated heterozygous deletions (HetDels) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ting-Ting, Li, Chien-Feng, Tan, Kien-Thiam, Jan, Yi-Hua, Lee, Pei-Hang, Huang, Chih-Hao, Yu, Shih-Chen, Tsao, Cheng-Feng, Wang, Jui-Chu, Huang, Hsuan-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997382/ https://www.ncbi.nlm.nih.gov/pubmed/35406559 http://dx.doi.org/10.3390/cancers14071787

Ejemplares similares

In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2
por: Kim, S, et al.
Publicado: (2008)

CHEK2 contribution to hereditary breast cancer in non-BRCA families
por: Desrichard, Alexis, et al.
Publicado: (2011)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers
por: Ge, Yuqiu, et al.
Publicado: (2016)

A case report of biallelic CHEK2 heterozygous variant presenting with breast cancer
por: Soleimani, Tahereh, et al.
Publicado: (2023)

Maternal heterozygous mutation in CHEK1 leads to mitotic arrest in human zygotes
por: Chen, Beili, et al.
Publicado: (2021)

Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
por: Wang, Yufei, et al.
Publicado: (2014)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series
por: Sukumar, Jasmine, et al.
Publicado: (2021)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors
por: Kinget, Lisa, et al.
Publicado: (2021)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014)

Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database
por: Bermejo, Justo Lorenzo, et al.
Publicado: (2004)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
por: Petridis, Christos, et al.
Publicado: (2019)

Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci
por: Djuzenova, Cholpon S, et al.
Publicado: (2013)

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
por: Kuusisto, Kirsi M, et al.
Publicado: (2011)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

BRCA1 and γH2AX as independent prognostic markers in oral squamous cell carcinoma
por: Oliveira-Costa, Joao Paulo, et al.
Publicado: (2014)

Association of genetic variants in ATR-CHEK1 and ATM-CHEK2 pathway genes with risk of colorectal cancer in a Chinese population
por: Wang, Shijia, et al.
Publicado: (2018)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

CHEK2 mutations in pediatric brain tumors
por: Tlais, Dana, et al.
Publicado: (2023)

Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients()
por: Park, See-Hyoung, et al.
Publicado: (2015)

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2016)

ATM Localization and Heterochromatin Repair Depend on Direct Interaction of the 53BP1-BRCT(2) Domain with γH2AX
por: Baldock, Robert A., et al.
Publicado: (2015)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals
por: Jekimovs, C R, et al.
Publicado: (2005)

Chemical proteomics reveals a γH2AX-53BP1 interaction in the DNA damage response
por: Kleiner, Ralph E., et al.
Publicado: (2015)

Aneuploidy in spermatids of Robertsonian (Rb) chromosome heterozygous mice
por: Manieu, Catalina, et al.
Publicado: (2014)

CHEK2 variants associate with hereditary prostate cancer
por: Seppälä, E H, et al.
Publicado: (2003)

The CHEK 2 GENE mutations and the risk of Gastric cancer
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

Current perspectives on CHEK2 mutations in breast cancer
por: Apostolou, Panagiotis, et al.
Publicado: (2017)

CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022)

H2AX Prevents CtIP-Mediated DNA End Resection and Aberrant Repair in G1-Phase Lymphocytes
por: Helmink, Beth A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_anlflu6m4iur2op3vrg0kt0d00